Document XzYwvOewjXzjGEoGBGpK26kBJ

f s\ | i ^ ri y CHEMICAL MANUFACTURERS ASSOCIATION Vinyl Chloride Health Committee Tentative Meeting Agenda DATE: TIME: PLACE: j^ril_23M997.,__ 9:30 a.m. - 3:00 p.m. DST Georgetown Conference Room 1.0 Approval of the February 18,1997 Record of Conference Call 2.0 Update on the Developmental, Reproductive and Mechanistic Research Studies c c*..------ G vL!_*--\-i.v --- -- , 2.1 Huntingdon Life Sciences Developmental and Reproductive Studies 2.2 University of North Carolina - j. Swenberg Satellite Study 2.3 Status of Progress Reports to ATSDR ^ <- . < \y'. > ^ 3.0 Update op the International Life Sciences Institute Genotoxicity Project * U. ^ <- 4.0 Update on EPA's IRIS Pilot Project ^ ^ 5.0 Update on the University of Louisville Brain Cancer Study Ff-, " <r - s. V. .. *- 6.0 Update on the Vinyl Chloride Cohort Study with Applied Epidemiology Inc. -- - v. .-v i'L vVv<v-\J yr 7.0 Update on ATSDR Activities C ,'V>i - v > f-r 7.1 Status of Comments on the Toxicological Profilefor Vinyl Chloride 7.2 Status of Activity on the Minimal Risk Level for Vinyl Chloride 7.3 Status of the Medical Management Practices Guideline 8.0 Financial Update ^-cArv-1--i~v^' s' r,-. ^ A 9.0 Schedule Next Meeting or Conference Call Subject to Approval CS_ J I jt- .OTP Wendy K. Sherman Manager Vinyl Chloride Health Committee , ,Kr-tC j(/o -y H ? A r- i ^ ~ ly '^c " tv j A. A 0 e. tl., '. .. A l < -r t" ' * s. "-v c'4v7.u BFG 00021 ANTITRUST CHECKLIST FOR CMA MEETINGS This antitrust checklist is for use by CMA staff and member representatives in the conduct of CMA-sponsored meetings. Prohibited discussion topics apply equally to social gatherings incidental to CMA-sponsored meetings. The Checklist is not exhaustive and does not address antitrust issues relating to activities other than CMA meetings. Participants in CMA meetings also should be thoroughly familiar with: (1) "Antitrust Guide for CMA Committee Members;7' and, (2) "General Principles Applicable to the Structure and Operations of Committees.7' Both of these documents may be found in the CMA Directory. DO Ensure strict performance in areas of: OVERSIGHT/SUPERVISION: Have a CMA staff representative at each CMAsponsored meeting (unless an exception has been authorized by the appropriate CMA vice president); consult with an attorney of the CMA Office of General Counsel on all antitrust questions relating to CMA-sponsored meetings; limit meeting discussions to agenda topics (unless additional topics have been approved by the appropriate CMA staff representative); and provide each member company representative and CMA staff representative attending a CMAsponsored meeting with a copy of this checklist, and have a copy available for reference at all CMA-sponsored meetings. RECORDKEEPING: Have an agenda and minutes which accurately reflect the matters which occur; provide agendas and minutes to the CMA Office of General Counsel for review and approval in advance of distribution; and, fully describe the purposes and authorities of all task groups, work groups, ad hoc or other standing committee subgroups in the minutes of the appropriate parent committee. VIGILANCE: Protest against any discussion or meeting activities which appear to violate this checklist; dissociate yourself from any such discussion or activities and leave any meeting in which they continue. DON'T Do not, in fact or appearance, discuss or exchange information on: PRICES, INCLUDING: Individual company prices, price changes, price differentials, markups, discounts, allowances, credit terms, etc.; individual company data on costs, production, capacity, inventories, sales, etc.; and, industry pricing policies, price levels, price changes, differentials, etc. PRODUCTION, INCLUDING: Plans of individual companies concerning the design, production, distribution or marketing of particular products, including proposed territories or customers; and, changes in industry production, capacity or inventories. TRANSPORTATION RATES: Rates or rate policies for individual shipments, including basing point systems, zone prices, freight equalization, etc. MARKET PROCEDURES, INCLUDING: Company bids on contracts for particular products; company procedures for responding to bid invitations; and, matters relating to actual or potential individual suppliers or customers that might have the effect of excluding them from any market or influencing the business conduct of firms toward them. CONSENT DECREE SUBSTANCE: Any matter relating to trisodium phosphate (a restriction required by a 1962 consent decree to which CMA is a party). Revised 3/80 (single page version) Reformatted 1/89 MDB; 6/96 SKR BFG 00022 CHEMICAL MANUFACTURERS ASSOCIATION Vinyl Chloride Health Committee Meeting With the University of Louisville Tentative Agenda DATE: April 18, 1997 TIME: 8:30 a.m. - 2:30 p.m. PLACE: Health Sciences Center University of Louisville Louisville, KY vV-. V--- v L' l'- r -2- S'- ; . 4, *.AU d. 8:30-9:00 1.0 Review Agenda Items and Objectives 9:00-9:30 2.0 Status of Work in Progress at the University of Louisville 9:30-9:45 3.0 Update on Cohort Mortality Study at the Applied Epidemiology, Inc. 9:45-10:15 10:45-11:00 4.0 Discussion ottpreenberg/Tamburro Methodology for Analysis'of BF Goodrich Cohort Data, Including Statistical Powers ^ ^r, L. ^ . rv .'3j-Jx -- \ Break T,. 11:00-12:00 5.0 s Discussion of ClassicaKlase Control Analysis ol^BF Goodrich Cohort Data 12:00-12:30 6.0 Consensus on Methods of Analysis and Publication of Final Study Results 12:30-1:30 Lunch 1:30-2:30 7.0 Development of Final Protocol 7.1 Review GEP's to Assure that the Final Protocol Meets All Applicable Guidelines 7.2 Develop a Strategy for Addressing Peer Reviewers Comments in the Protocol 7.3 Establish a Time Line for Preparation, Reviews, and Approval of Final Protocol 7.4 Discuss Peer Reviewers' Sign-off of the Final Protocol ' - ----------'\ '*Zf*^*. x IrU. vA BFG 00023 'X ^ i ^ --4 -- '*--^'w l_ fA C V-f K. U- UA P c--1 fi*ft). r 4 /^ .i; ; tzr 4 f-Wv . ' t ^ O < ` >. * k ..* . `/0 t``(\ v>^. . --tf-V. \_ V'S-X.-'r''S--'SJj V' *'- ' ~ ' <' '~" ~ *:_< L t -4^' *-,, C- C ^ -w^y (f L'-~ -- '-* 1 ^ ** ^ r - -U,tri( i.j ) l' ^ >- -'V c'-- -> i ^ A -- c V ^ ^ t-v ^. r. pc I'fPo ?l 4 a*' y-' C<- ww ____ \_'_> <-' /l`\ . A-' ^ ~r 4 ~i / - t't ^ y '.AO-- ;\ . i '-^i- -' H'J> A-O. \ C -<-y _vjA,''~A_A^v'k..V..'- `'^---5-<-->--V a tv_'-oi > ! 'J'*- l' v- VVJ j.~VL _,w4_^_S W?'--JC A -- - Y- f ^ >c -V --- \ C A; ^ .<c-- >.<-4^ V' I/-'*,' V- V. \. ' r k ._?' v ^ 4 `|'V`f' c^'. r : <^ < \ ci r < r y iA./f'y < '(.. .; l /WrT*>> v' ?A *i C- A n t W'Tt 4r~ LX t>X 4 i r- '< V ' y * .. ,> vV- -- /v '- ^ 'Ki \r- - >- ^ ''-'t 'X ~ 14o.A-4 vi-^ pc V .,- . v . . v .. \ t '? BFG 00024 FROM: CMA Hh'K-ib-iyy/ 4-16-1997 8:02 PAGE 2/2 Via Electronic FAX Cl IEM1CAL MANUFACTURERS ASSOCIAHON Vinyl Chloride Health Committee Tentative Meeting Agenda DATE: TIME: PLACE: April 23,1997 9:30 am-3:00 pm D5T Georgetown Conference Room l .0 Approval of the February 18,1997 Record of Conference Call 2.0 Update on the Developmental, Reproductive and Mechanistic Research Studies 2.1 Huntingdon Life Sciences Developmental and Reproductive Studies 2.2 University of North Carolina - J. Swenberg Satellite Study 2.3 Status of Progress Reports to AT5DR 3.0 Update on the International Life Sciences Institute Genotoxicity Project 4.0 Update on ETA's IRIS Tilot Project 5.0 Update on the University of Louisville Brain Cancer Study 6.0 Update on the Vinyl Chloride Cohort Study with Applied Epidemiology Inc. 7.0 Update on ATSDR Activities 7.1 Status of Comments on the Toxicologicut Profilefor Vinyl ChlvriUc 7.2 Status of Activity on the Minimal Risk Level for Vinyl Chloride 7.3 Status of the Medical Management Practices Guideline 8.0 Financial Update 9.0 Schedule Next Meeting or Conference Call Subject to Approval Wendy K. Sherman Manager Vinyl Chloride Health Committee BFG 00025 TOTAL P.001